ADO-Trastuzumab Emtansine, also known as Kadcyla, is an antibody-drug conjugate (ADC) developed by Genentech, a member of the Roche Group.

Marengo shares encouraging initial human safety, tolerability, and clinical activity results for its lead candidate, Invikafusp Alfa (STAR0602).

The application of AI technology in new drug development spans several critical stages, from compound synthesis to drug repurposing.

STORM Therapeutics reveals that it shared encouraging findings from its Phase 1 clinical trial of STC-15, an inhibitor targeting METTL3 RNA methyltransferase.

Fentanyl Citrate is a small molecule drug that targets the μ opioid receptor and is used to treat a range of therapeutic areas including nervous system diseases.

NGGT recently shared promising new data regarding NGGT002, their gene therapy candidate currently in clinical trials for addressing Phenylketonuria (PKU).

Fomivirsen, developed by Isis Pharmaceuticals, is an antisense oligonucleotide that targets the messenger RNA (mRNA) of cytomegalovirus (CMV).

Theragent and CellVax Therapeutics have reported the initial dosing of a patient in their Phase 2 study of FK-PC101, a new personalized cancer immunotherapy.

Osimertinib mesylate is a small molecule drug that targets EGFR L858R, EGFR T790M, and EGFR-Ex19del.

Allogene Therapeutics shared promising Phase 1 results showcasing ALLO-316's potential in advanced renal cell carcinoma patients at SITC and IKCS.

Eculizumab is a humanized monoclonal antibody that targets the complement protein C5. Developed by Alexion Pharmaceuticals.

Fate Therapeutics Shares Preclinical Data on FT836, a MICA/B-targeted CAR T-cell, at 2024 SITC Meeting.